SARS-COV-2 SPIKE PROTEIN ANTIBODIES

Smart overview of the Invention

A new class of antibodies that specifically bind to the spike protein of SARS-CoV-2 has been developed, along with associated compositions and methods for their use. These antibodies aim to provide therapeutic, preventive, and diagnostic solutions for SARS-CoV-2 infections, which have led to a global pandemic since late 2019.

Background on Coronaviruses

Coronaviruses are known to cause mild respiratory illnesses but have the potential to lead to severe diseases, as seen with SARS-CoV-2. This virus has caused significant morbidity and mortality worldwide, with millions of cases and deaths reported. Despite ongoing clinical trials exploring various treatments, effective therapies for COVID-19 remain limited.

Development of Anti-CoV-S Antibodies

The disclosed antibodies are designed to target the spike protein (CoV-S) of SARS-CoV-2. They include specific antigen-binding domains derived from various antibody clones, which are crucial for the neutralization of the virus. These antibodies can be utilized in different forms, including isolated antibodies or as part of pharmaceutical compositions.

Methods of Use

The application outlines methods for producing these antibodies through cultured host cells and expression vectors. Additionally, it describes their potential applications in treating or preventing SARS-CoV-2 infections and detecting the presence of the virus in human samples through binding assays.

Conclusion and Future Implications

The innovation presented offers a promising avenue for combating SARS-CoV-2 by leveraging advanced antibody technologies. As research continues, these antibodies may play a critical role in addressing current gaps in COVID-19 treatment and prevention strategies.